Stock Evaluator: GH Research PLC (GHRS)

GH Research PLC GHRS

$18.25 -0.02 -0.11%
November 18, 2026 4:00:00 PM EST November 10, 2021 Volume: 461,965
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company’s lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Commentary & Analysis


Financial Summary

Share Statistics GHRS Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $1,254.1 $436.9 49%
Shares Out (Mil) 66.5 46.5 53%
Institutional Ownership 65.5% 82.2% 41%
Float (Mil) 32.4 47.7 37%
Beta na 0.68 na
Avg Daily Volume (000s) 331 339 51%
Price Change
(52-week)
30.5% 52.1% 77%
Growth GHRS Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 6.6% na
Net Income (5yr) (160.8%) (1.6%) 1%
EPS (5yr) (118.2%) 15.1% 1
Dividends (5yr) na 0.0% na
Cash Flow (5yr) 65.8% (15.1%) 96%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 8 8 9
Current EPS ($0.270) ($0.980) ($1.638)
Month Ago EPS ($0.351) ($1.174) ($1.850)
# Rev Up 0 0 0
# Rev Down 1 2 1
Three Months Ago EPS ($0.351) ($1.174) ($1.850)
Year/Year Chg 18.4% 23.9% 124.1%
Financials GHRS Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $289 na
Net Income (TTM) (Mil) ($62) ($11) 14%
EPS (TTM) ($0.986) ($0.600) 21%
Operating Cash Flow (TTM) (Mil) ($52) ($7) 10%
Net Cash Flow (TTM) (Mil) $91 $1 76%
Long-Term Debt (Q1) (Mil) $0 $6 0%
Enterprise Value (Q1) (Mil) $949 $331 41%
Valuation GHRS Industry
Median
Percentile
(All Stocks)
P/B 3.49 2.15 73%
P/E na 24.2 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.2 na
Ratios GHRS Industry
Median
Percentile
(All Stocks)
Gross Margin na 69.5% na
Net Margin na 3.6% na
ROA (18.2%) (23.3%) 20%
ROE (18.8%) (24.7%) 23%
Liabilities to Assets 3.5% 31.8% 1%
F-Score 2 3 7%

GH Research PLC did not pass any screens on 11/17/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors